Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent

Diabetes Care

Volumn 33, Issue 6, 2010, Pages 1262-1268

  Gresele, Paolo ^a   Marzotti, Stefania ^a   Guglielmini, Giuseppe ^a   Momi, Stefania ^a   Giannini, Silvia ^a   Minuz, Pietro ^b   Lucidi, Paola ^a   Bolli, Geremia B ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; CYCLOOXYGENASE 1; GLUCOSE; INSULIN; METFORMIN; NITRATE; NITRITE; PLACEBO; REPAGLINIDE; SULFONYLUREA DERIVATIVE; THROMBOXANE B2; VON WILLEBRAND FACTOR; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; NITRIC OXIDE DONOR;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DUODENUM ULCER; ENZYME INHIBITION; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HEART RATE; HUMAN; HYPERGLYCEMIA; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SHEAR STRESS; SIDE EFFECT; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TREATMENT DURATION; ADOLESCENT; FLOW CYTOMETRY; MIDDLE AGED; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; AGED; ASPIRIN; FEMALE; FLOW CYTOMETRY; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; NITRIC OXIDE DONORS; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; YOUNG ADULT;

EID: 77956090233     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-2013     Document Type: Article

References (25)

1. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-240
2. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54:1-7
3. Angiolillo DJ, Bernardo E, Sabaté M, Jimenez- Quevedo P, Costa MA, Palazuelos J, Hernández-Antolin R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Guzman LA, Bass TA, Macaya C, Fernandez-Ortiz A. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50:1541-1547
4. Gresele P, Guglielmini G, De Angelis M, Ciferri S, Ciofetta M, Falcinelli E, Lalli C, Ciabattoni G, Davì G, Bolli GB. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003;41:1013-1020
5. Colwell JA, Nesto RW. The platelets in diabetes: focus on prevention of ischemic events. Diabetes Care 2003;26:2181-2188
6. Frankel DS, Meigs JB, Massaro JM, Wilson PW, O'Donnell CJ, D'Agostino RB, Tofler GH. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the Framingham offspring study. Circulation 2008;118:2533-2539
7. Barstad RM, Orvim U, Hamers MJ, Tjønnfjord GE, Brosstad FR, Sakariassen KS. Reduced effect of aspirin on thrombus formation at high shear and disturbed laminar blood flow. Thromb Haemost 1996;75:827-832
8. Anfossi G, Russo I, Trovati M. Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Curr Vasc Pharmacol 2008;6:313-328
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J. 2002;324:71-86
10. Martelli A, Breschi MC, Calderone V. Pharmacodynamic hybrids coupling established cardiovascular mechanisms of action with additional nitric oxide releasing properties. Curr Pharm Des 2009;15:614-636
11. Gresele P, Momi S. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc Drug Rev 2006;24:148-168
12. Gresele P, Migliacci R, Procacci A, De Monte P, Bonizzoni E. Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication. Thromb Haemost 2007;97:444-450
13. Carini M, Aldini G, Orioli M, Piccoli A, Tocchetti P, Facino RM. Chemiluminescence and LC-MS/MS analyses for the study of nitric oxide release and distribution following oral administration of nitroaspirin (NCX 4016) in healthy volunteers. J Pharm Biomed Anal 2004;35:277-287
14. Falcinelli E, Giannini S, Boschetti E, Gresele P. Platelets release active matrix metalloproteinase- 2 in vivo in humans at a site of vascular injury: lack of inhibition by aspirin. Br J Haematol 2007;138:221-230 (Pubitemid 46976318)
15. O'Brien JR, Salmon GP. Shear stress activation of platelet glycoprotein IIb/IIIa plus von Willebrand factor causes aggregation: filter blockage and the long bleeding time in von Willebrand's disease. Blood 1987;70:1354-1361
16. Bossavy JP, Sakariassen KS, Barret A, Boneu B, Cadroy Y. A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis. Thromb Haemost 1998;79:162-168
17. Pitchford SC, Yano H, Lever R, Riffo- Vasquez Y, Ciferri S, Rose MJ, Giannini S, Momi S, Spina D, O'Connor B, Gresele P, Page CP. Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol 2003;112:109-118
18. Corazzi T, Leone M, Maucci R, Corazzi L, Gresele P. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). J Pharmacol Exp Ther 2005;315:1331-1137
19. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992;85:2284-2290
20. Ferroni P, Basili S, Falco A, Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004;2:1282-1291
21. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 1987;69:180-186
22. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772
23. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002;90:21-28
24. Kaddai V, Gonzalez T, Bolla M, Le Marchand- Brustel Y, Cormont M. The nitric oxide-donating derivative of acetylsalicylic acid, NCX 4016, stimulates glucose transport and glucose transporters translocation in 3T3-L1 adipocytes Am J Physiol Endocrinol Metab 2008;295:E162-E169
25. Lazzarato L, Donnola M, Rolando B, Marini E, Cena C, Coruzzi G, Guaita E, Morini G, Fruttero R, Gasco A, Biondi S, Ongini E. Searching for new NO-donor aspirin-like molecules: a new class of nitrooxy- acyl derivatives of salicylic acid. J Med Chem 2008;51:1894-1903